Shedding new light on RhoA signalling as a drug target in vivo using a novel RhoA-FRET biosensor mouse

Max Nobis1, David Herrmann1, Sean C Warren1

  • 1The Garvan Institute of Medical Research, St Vincent's Clinical School, Faculty of Medicine, University of New South Wales , Sydney, 2010 NSW, Australia.

Small Gtpases
|February 20, 2018
PubMed

Insights

Researchers developed a novel RhoA-FRET biosensor mouse to study RhoA signaling in vivo. This tool enables real-time observation of RhoA activity in various physiological and pathological conditions, aiding in the development of new cancer therapies.

Area of Science:

  • Cellular signaling and mechanotransduction
  • Cancer biology and therapeutics
  • In vivo imaging and biosensing

Background:

  • The small GTPase RhoA is a key regulator of cell-extracellular matrix interactions, crucial for processes like migration and mechanotransduction.
  • Dysregulated RhoA signaling is implicated in carcinogenesis, but studying its activity in native tissues is challenging with conventional methods.
  • Intravital imaging offers a promising approach for real-time analysis of cellular signaling within living organisms.

Purpose of the Study:

  • To develop and validate a RhoA-FRET biosensor mouse for investigating RhoA activity in vivo.
  • To utilize this tool to explore RhoA signaling dynamics in diverse physiological and pathological contexts.
  • To enable temporal resolution of pharmacological interventions targeting RhoA signaling in vivo.

Main Methods:

  • Development of a genetically engineered mouse model expressing a RhoA-Förster Resonance Energy Transfer (FRET) biosensor.
  • Application of intravital imaging techniques to visualize RhoA activity in various tissues and conditions.
  • Analysis of RhoA signaling during mechanotransduction, neutrophil migration, tissue remodeling, and carcinogenesis.

Main Results:

  • Demonstrated RhoA-FRET mouse's capability to visualize RhoA activity in osteocyte mechanotransduction, neutrophil chemotaxis, and mammary gland remodeling.
  • Observed tightly regulated RhoA activity during mammary and pancreatic carcinogenesis.
  • Successfully resolved the temporal effects of RhoA inhibition in established mammary and pancreatic tumors in vivo.

Conclusions:

  • The RhoA-FRET biosensor mouse is a powerful tool for studying RhoA signaling in native tissue environments.
  • This model facilitates real-time investigation of RhoA's role in diverse biological processes and diseases.
  • The developed tool can accelerate the discovery and development of novel therapeutic inhibitors targeting the RhoA signaling axis.

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.5K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
3
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
4
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
2
What is Cell Signaling?02:03

What is Cell Signaling?

Despite the protective membrane that separates a cell from the environment, cells need the ability to detect and respond to environmental changes. Additionally, cells often need to communicate with one another. Unicellular and multicellular organisms use a variety of cell signaling mechanisms to communicate to respond to the environment.
131.1K
Endocrine Signaling01:45

Endocrine Signaling

Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
68.2K